Skip to main content
HIMS logo

HIMS

Hims & Hers Health, Inc. Class A

$26.00

8.06%

Trade Ideas Performance

Latest Closed Trade Idea

$26.00

8.06%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

0

Social

5

About

Events of Hims & Hers Health, Inc. Class A (HIMS)

Over the past six months (May 2026 to November 2026), HIMS stock increased by 1.52% but declined by 23.8% in the three months leading up to November 2026. In November 2026, the company announced a direct partnership with Eli Lilly to offer branded obesity treatments, including Zepbound and Foundayo, which caused an 8% jump in shares. This follows a similar deal with Novo Nordisk in March 2026 for Wegovy and Ozempic, marking a strategic shift from compounded to branded obesity medications. This pivot led to financial pressure, with losses of $92 million in Q1 2026 and $86 million in Q2 2026 due to restructuring costs related to its compounded GLP-1 supply chain. The company is scheduled to release its Q3 2026 earnings on November 9, 2026, with analysts anticipating strong revenue growth from weight loss momentum and international expansion.

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)